Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 1Polycythemia Vera 1

Interventions

Specimen Handling 49pembrolizumab 44Magnetic Resonance Spectroscopy 37Biopsy 35Cyclophosphamide 33fludarabine 28Cetuximab 20Cisplatin 19Carboplatin 19Bevacizumab 16atezolizumab 15Radiation 15venetoclax 14Fluorouracil 14fludarabine phosphate 13Radiotherapy 13Leucovorin 13Nivolumab 12Gemcitabine 12Pemetrexed 11Oxaliplatin 11Cytarabine 11Irinotecan 10130-nm albumin-bound paclitaxel 10Prednisone 9Paclitaxel 9Immunoglobulin G 9Fulvestrant 9durvalumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × umbralisib × 30 days × Clear all
NCT02493530 2026-05-19

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Vanderbilt-Ingram Cancer Center

Phase 1 Completed
60 enrolled
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡